Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13486Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gaikwad, Anil Bhanudas | - |
| dc.date.accessioned | 2023-12-21T08:52:21Z | - |
| dc.date.available | 2023-12-21T08:52:21Z | - |
| dc.date.issued | 2017-09 | - |
| dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830845/ | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13486 | - |
| dc.description.abstract | Although cardioprotective effects of telmisartan are well explored, its effects on epigenetic alterations associated with type 2 diabetic (T2D) cardiomyopathy remain unmapped. Thus, the present study was designed to evaluate the potential of esculetin and telmisartan combination to reverse histone posttranslational modifications (PTMs) in curbing T2D cardiomyopathy. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | PMC | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Telmisartan | en_US |
| dc.subject | H2B histone | en_US |
| dc.subject | Type 2 diabetic (T2D) | en_US |
| dc.title | Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.